Shares of Diurnal Group PLC (LON:DNL) reached a new 52-week high during mid-day trading on Monday following insider buying activity. The company traded as high as GBX 173 ($2.35) and last traded at GBX 170 ($2.31), with a volume of 14277 shares traded. The stock had previously closed at GBX 170 ($2.31).
Specifically, insider John Goddard acquired 10,791 shares of the stock in a transaction dated Friday, January 5th. The stock was purchased at an average cost of GBX 540 ($7.32) per share, with a total value of £58,271.40 ($79,022.78). Also, insider Martin Whitaker acquired 3,703 shares of the stock in a transaction dated Monday, November 27th. The stock was acquired at an average cost of GBX 135 ($1.83) per share, with a total value of £4,999.05 ($6,779.29).
Separately, Numis Securities reissued a “buy” rating and issued a GBX 185 ($2.51) price objective on shares of Diurnal Group in a research report on Monday, December 18th.
Diurnal Group Company Profile
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with our FREE daily email newsletter.